Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
American Journal of Hematology|August 9, 2016
Outcomes of patients with renal monoclonal immunoglobulin deposition diseaseTaxiarchis V Kourelis, Samih H Nasr, Angela Dispenzieri, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Blood Cancer Journal|March 30, 2026
Management of hematological toxicities after BCMA-directed CAR-T cell therapyJoselle Cook, Supriya Gupta, Nadine Abdallah, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Pageof 9